Previous close | 11.60 |
Open | 11.50 |
Bid | 11.50 x 150000 |
Ask | 12.10 x 150000 |
Day's range | 11.60 - 11.60 |
52-week range | 11.10 - 18.10 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 08 Feb 2023 - 13 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement (the "credit agreement") with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross p
In the latest trading session, Innoviva (INVA) closed at $13.27, marking a +0.15% move from the previous day.
In the latest trading session, Innoviva (INVA) closed at $13.03, marking a -1.06% move from the previous day.